Skip to main content
Erschienen in: Current Diabetes Reports 10/2015

01.10.2015 | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Hypoglycemia and Comorbidities in Type 2 Diabetes

verfasst von: Alice P. S. Kong, Juliana C. N. Chan

Erschienen in: Current Diabetes Reports | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Hypoglycemia is one of the major barriers in optimizing glycemic control. In type 2 diabetes, hypoglycemia is associated with multiple morbidities (eg, myocardial ischemia, cardiac arrhythmia, stroke, dementia, psychosocial dysfunction, obesity, microvascular complications, cancer, and diseases of respiratory, digestive, and dermatological systems). Risk factors associated with hypoglycemia in patients with type 2 diabetes include old age, long disease duration, low body mass index, high baseline glycated hemoglobin (HbA1c), treatment with insulin and sulphonylurea, renal dysfunction, albuminuria, reduced level of low density lipoprotein cholesterol, low triglyceride and depression. There are considerable overlaps between phenotypes associated with severe hypoglycemia and all-site cancer suggesting that hypoglycemia may be a marker of vulnerability. In patients with severe hypoglycemia, comprehensive assessment is recommended to detect silent conditions, such as renal dysfunction, cancer, depression as well as review of treatment strategies including drug use to prevent morbidities and mortality.
Literatur
1.
Zurück zum Zitat UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
2.
Zurück zum Zitat Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomised prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomised prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed
3.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMed
4.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMed Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMed
5.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed
6.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.CrossRefPubMed Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.CrossRefPubMed
7.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed
8.
Zurück zum Zitat Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.PubMedCentralCrossRefPubMed Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–7.CrossRefPubMed Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–7.CrossRefPubMed
10.
Zurück zum Zitat Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–8.CrossRefPubMed Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–8.CrossRefPubMed
11.
Zurück zum Zitat Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353–63.CrossRefPubMed Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353–63.CrossRefPubMed
12.
Zurück zum Zitat Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26(5):1485–9.CrossRefPubMed Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26(5):1485–9.CrossRefPubMed
14.
Zurück zum Zitat Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–47.CrossRefPubMed Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–47.CrossRefPubMed
15.
Zurück zum Zitat Hoffman RP. Sympathetic mechanisms of hypoglycemic counterregulation. Curr Diabetes Rev. 2007;3(3):185–93.CrossRefPubMed Hoffman RP. Sympathetic mechanisms of hypoglycemic counterregulation. Curr Diabetes Rev. 2007;3(3):185–93.CrossRefPubMed
16.
Zurück zum Zitat Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51(1):5–14.CrossRefPubMed Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51(1):5–14.CrossRefPubMed
17.
Zurück zum Zitat Shih CJ, Wu YL, Lo YH, et al. Association of hypoglycemia with incident chronic kidney disease in patients with type 2 diabetes: a nationwide population-based study. Medicine (Baltimore). 2015;94(16), e771.CrossRef Shih CJ, Wu YL, Lo YH, et al. Association of hypoglycemia with incident chronic kidney disease in patients with type 2 diabetes: a nationwide population-based study. Medicine (Baltimore). 2015;94(16), e771.CrossRef
18.
Zurück zum Zitat Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care. 2013;36(4):894–900.PubMedCentralCrossRefPubMed Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care. 2013;36(4):894–900.PubMedCentralCrossRefPubMed
19.•
Zurück zum Zitat Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong Diabetes Registry. Diabetes Care. 2014;37:1–8. This study highlights the overlaps between phenotypes associated with cancer and hypoglycemia in patients with type 2 diabetes. CrossRef Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong Diabetes Registry. Diabetes Care. 2014;37:1–8. This study highlights the overlaps between phenotypes associated with cancer and hypoglycemia in patients with type 2 diabetes. CrossRef
20.
Zurück zum Zitat Kong AP, Chan JC. Cancer risk in type 2 diabetes. Curr Diabetes Rep. 2012;12(4):325–8.CrossRef Kong AP, Chan JC. Cancer risk in type 2 diabetes. Curr Diabetes Rep. 2012;12(4):325–8.CrossRef
21.
Zurück zum Zitat Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264–70.CrossRefPubMed Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264–70.CrossRefPubMed
22.
Zurück zum Zitat Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol. 2015;11(6):372–9. Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol. 2015;11(6):372–9.
23.
Zurück zum Zitat Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25(6):971–1010.CrossRefPubMed Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25(6):971–1010.CrossRefPubMed
24.
Zurück zum Zitat Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in nonclinical trial settings--what, why and how? Diabetes Obes Metab. 2012;14(7):579–85.CrossRefPubMed Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in nonclinical trial settings--what, why and how? Diabetes Obes Metab. 2012;14(7):579–85.CrossRefPubMed
25.
Zurück zum Zitat Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16.PubMedCentralCrossRefPubMed Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Kong AP, Yang X, So WY, et al. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. BMC Med. 2014;12(76):1–11. Kong AP, Yang X, So WY, et al. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. BMC Med. 2014;12(76):1–11.
27.
Zurück zum Zitat Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.CrossRefPubMed Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.CrossRefPubMed
28.
Zurück zum Zitat Carton JA, Maradona JA, Nuno FJ, Fernandez-Alvarez R, Perez-Gonzalez F, Asensi V. Diabetes mellitus and bacteraemia: a comparative study between diabetic and nondiabetic patients. Eur J Med. 1992;1(5):281–7.PubMed Carton JA, Maradona JA, Nuno FJ, Fernandez-Alvarez R, Perez-Gonzalez F, Asensi V. Diabetes mellitus and bacteraemia: a comparative study between diabetic and nondiabetic patients. Eur J Med. 1992;1(5):281–7.PubMed
29.
Zurück zum Zitat Aragon D, Ring CA, Covelli M. The influence of diabetes mellitus on postoperative infections. Crit Care Nurs Clin N Am. 2003;15(1):125–35.CrossRef Aragon D, Ring CA, Covelli M. The influence of diabetes mellitus on postoperative infections. Crit Care Nurs Clin N Am. 2003;15(1):125–35.CrossRef
30.••
Zurück zum Zitat Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–22. This review has comprehensive review of the topic of hypoglycemia in patients with diabetes. CrossRefPubMed Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–22. This review has comprehensive review of the topic of hypoglycemia in patients with diabetes. CrossRefPubMed
31.
Zurück zum Zitat Lorber D, Anderson J, Arent S, et al. Diabetes and driving. Diabetes Care. 2014;37 Suppl 1:S97–103.PubMed Lorber D, Anderson J, Arent S, et al. Diabetes and driving. Diabetes Care. 2014;37 Suppl 1:S97–103.PubMed
32.
Zurück zum Zitat Del Prato S, LaSalle J, Matthaei S, Bailey CJ. Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract. 2010;64(3):295–304.PubMedCentralCrossRefPubMed Del Prato S, LaSalle J, Matthaei S, Bailey CJ. Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract. 2010;64(3):295–304.PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Lawton J, Rankin D, Elliott J, et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37(1):109–15.CrossRefPubMed Lawton J, Rankin D, Elliott J, et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37(1):109–15.CrossRefPubMed
34.
Zurück zum Zitat Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab. 2005;7(5):493–503.CrossRefPubMed Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab. 2005;7(5):493–503.CrossRefPubMed
35.
Zurück zum Zitat Whitmer RA, Karter AJ, Yaffe K, Quesenberry Jr CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–72.PubMedCentralCrossRefPubMed Whitmer RA, Karter AJ, Yaffe K, Quesenberry Jr CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–72.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Int Med. 2013;173(14):1300–6.CrossRef Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Int Med. 2013;173(14):1300–6.CrossRef
37.
Zurück zum Zitat Zhang Y, Ting RZ, Yang W, et al. Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. J Diabetes. 2014. doi:10.1111/1753-0407.12238. Zhang Y, Ting RZ, Yang W, et al. Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. J Diabetes. 2014. doi:10.​1111/​1753-0407.​12238.
38.
Zurück zum Zitat Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf. 2012;11(4):597–614.CrossRefPubMed Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf. 2012;11(4):597–614.CrossRefPubMed
39.
Zurück zum Zitat So WY, Chan JC, Yeung VT, et al. Sulphonylurea-induced hypoglycaemia in institutionalized elderly in Hong Kong. Diabetes Med. 2002;19(11):966–8.CrossRef So WY, Chan JC, Yeung VT, et al. Sulphonylurea-induced hypoglycaemia in institutionalized elderly in Hong Kong. Diabetes Med. 2002;19(11):966–8.CrossRef
40.
Zurück zum Zitat Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Diabetes Technol Ther. 2014;16(9):567–75.CrossRefPubMed Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Diabetes Technol Ther. 2014;16(9):567–75.CrossRefPubMed
41.
Zurück zum Zitat Asche CV, Luo W, Aagren M. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials. Curr Med Res Opin. 2013;29(10):1287–96.CrossRefPubMed Asche CV, Luo W, Aagren M. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials. Curr Med Res Opin. 2013;29(10):1287–96.CrossRefPubMed
42.
Zurück zum Zitat Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–7.PubMedCentralCrossRefPubMed Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–7.PubMedCentralCrossRefPubMed
43.
Zurück zum Zitat Ma RC, Kong AP, Chan N, Tong PC, Chan JC. Drug-induced endocrine and metabolic disorders. Drug Saf. 2007;30(3):215–45.CrossRefPubMed Ma RC, Kong AP, Chan N, Tong PC, Chan JC. Drug-induced endocrine and metabolic disorders. Drug Saf. 2007;30(3):215–45.CrossRefPubMed
44.
Zurück zum Zitat Kong AP, Yang X, Luk A, et al. Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocr Disord. 2014;14(1):48.PubMedCentralCrossRefPubMed Kong AP, Yang X, Luk A, et al. Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocr Disord. 2014;14(1):48.PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev. 2010;26(4):239–44.CrossRefPubMed Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev. 2010;26(4):239–44.CrossRefPubMed
46.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMed
47.•
Zurück zum Zitat Soe K, Sacerdote A, Karam J, Bahtiyar G. Management of type 2 diabetes mellitus in the elderly. Maturitas. 2011;70(2):151–9. This article provides evidence-based recommendations for management of elderly with diabetes which is an excellent example to illustrate the importance of personalized approach in diabetes care. CrossRefPubMed Soe K, Sacerdote A, Karam J, Bahtiyar G. Management of type 2 diabetes mellitus in the elderly. Maturitas. 2011;70(2):151–9. This article provides evidence-based recommendations for management of elderly with diabetes which is an excellent example to illustrate the importance of personalized approach in diabetes care. CrossRefPubMed
48.
Zurück zum Zitat Yang X, Wang Y, Luk AO, et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer. 2013;20(2):161–71.CrossRefPubMed Yang X, Wang Y, Luk AO, et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer. 2013;20(2):161–71.CrossRefPubMed
49.
Zurück zum Zitat Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008;179(5):427–37.PubMedCentralCrossRefPubMed Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008;179(5):427–37.PubMedCentralCrossRefPubMed
50.
Zurück zum Zitat Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care. 2009;32(10):1826–32.PubMedCentralCrossRefPubMed Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care. 2009;32(10):1826–32.PubMedCentralCrossRefPubMed
Metadaten
Titel
Hypoglycemia and Comorbidities in Type 2 Diabetes
verfasst von
Alice P. S. Kong
Juliana C. N. Chan
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 10/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0646-x

Weitere Artikel der Ausgabe 10/2015

Current Diabetes Reports 10/2015 Zur Ausgabe

Genetics (AP Morris, Section Editor)

Genetics of Type 2 Diabetes in African Americans

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Abnormalities of the Exocrine Pancreas in Type 1 Diabetes

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Mechanisms of Beta Cell Dysfunction Associated With Viral Infection

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Novel Therapies in Development for Diabetic Macular Edema

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.